Early Feasibility Study of Somatostatin Receptors PET Imaging for the Diagnosis of Infective Endocarditis

• Status: Not yet recruiting
• Trial end date: 2024-01-01
• Target enrollment: 0
• Participant gender: All

Summary

Study hypothesis: 68Ga-DOTATOC PET/CT could detect cardiac foci of infective endocarditis regardless of the type of valve (native or prosthetic) and also extracardiac localizations related to this pathology (infection responsible, peripheral emboli, ...). This study is a proof of concept with low population

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Central Hospital, Nancy, France
• Treatments: Edotreotide

Criteria

Inclusion Criteria:

• Adult who has received full information about the organisation of the research and has signed informed consent adult

• Participant hospitalised for definite AE according to modified Duke criteria (Li), on native or prosthetic valve, referred for 18F-FDG PET/CT from Cardiology and Infectious Diseases departments

Exclusion Criteria:

• Person with a history of hypersensitivity from previous use of 68Ga-DOTATOC

• Unable to perform a 68Ga-DOTATOC PET scan (agitated, confused patient...).

• Inability to schedule 68Ga-DOTATOC PET/CT the day after 18F-FDG PET/CT.

• Person with severe renal impairment (GFR <30 ml/min/1.73 m2)

• Participant treated with a somatostatin analogue.

• Participant with Cushing's syndrome

• Pregnant, potentially pregnant or breastfeeding women

• Adult subject to a legal protection measure (guardianship, curatorship, safeguard of justice)

• Person of full age who is unable to give consent

• Person deprived of liberty by a judicial or administrative decision

• Person subject to psychiatric care by virtue of Articles L. 3212-1 and L. 3213-1